Thanks. I think this is key.
"the FDA said they can only present one group of patients that have one cancer type"
Mgmt changed there language on a lot of things this time, and I think this is the reason they were talking about addition trials for cf33 for the first time really.
I think cf33 is extremely promising, but I do wonder how timeframes have been impacted across the board after this latest roadshow.
GLTA.
Ann: Imugene Corporate Presentation, page-225
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.7¢ |
Change
-0.002(3.39%) |
Mkt cap ! $418.9M | |||
| Open | High | Low | Value | Volume |
| 6.0¢ | 6.2¢ | 5.7¢ | $1.580M | 26.48M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 2857089 | 5.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.8¢ | 882472 | 30 |
View Market Depth
| Last trade - 14.02pm 15/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |